19 March 2024 : Original article
Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis
Wilfried Gwinner1ABDE*, Swapneel Anaokar2ACDE, Martin Blogg2ACDE, Birgit Hermann3ACDE, Carola del Pilar Repetur2CDE, Mario Schiffer4ABDEDOI: 10.12659/AOT.942167
Ann Transplant 2024; 29:e942167
Table 4 Kaplan-Meier estimates of freedom from the primary composite endpoint stratified by population cohort (first 5 years post-transplant).
| KM rate estimate (95% CI) | Year | Cohort | |||
|---|---|---|---|---|---|
| De novo (n=101) | Early conversion (n=12) | Late conversion (n=50) | Full analysis (N=163) | ||
| Composite | 1 | 0.691 (0.591–0.772) | 0.500 (0.208–0.736) | 0.680 (0.532–0.790) | 0.673 (0.595–0.739) |
| 2 | 0.638 (0.535–0.724) | 0.500 (0.208–0.736) | 0.640 (0.491–0.756) | 0.628 (0.549–0.698) | |
| 3 | 0.616 (0.512–0.704) | 0.500 (0.208–0.736) | 0.620 (0.471–0.738) | 0.608 (0.528–0.679) | |
| 4 | 0.547 (0.442–0.641) | 0.500 (0.208–0.736) | 0.620 (0.471–0.738) | 0.567 (0.486–0.640) | |
| 5 | 0.512 (0.407–0.608) | 0.500 (0.208–0.736) | 0.594 (0.443–0.717) | 0.537 (0.455–0.612) | |
| CI – confidence interval; KM – Kaplan-Meier. The KM estimates of individual components are presented only as a sensitivity analysis of the primary endpoint owing to potential bias due to the competing risks of occurrence of the other primary endpoint components. | |||||